Frank Jaksch, founder and chief scientific officer of ChromaDex, helps Dateline NBC’s Chris Hansen expose frauds in the dietary supplement space.
Investment Highlights
Potential $485 million to $600 million market opportunity for the Company's pTeroPure product
Client base includes the FDA, Cargill, Nestle, Kraft, Pfizer, and the USDA
Nationwide launch of Company?s first retail product line, BluScience, in GNC stores in 3Q11
Global Industry Analysts, a market research firm, forecasts that the global nutraceutical market will reach $243 billion by 2015
Phillip Frost, a Forbes 400 billionaire and Vice Chairman of Teva Pharmaceuticals, is a key investor in the Company
Partnered with global leaders Alcone and Chandler Chicco to advance proprietary products and branded retail lines
Financial Highlights
Overview
Founded in 1999, ChromaDex Corporation ("ChromaDex" or "the Company") is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary, supplement, food and beverage, cosmetic, and pharmaceutical industries. ChromaDex is leveraging this legacy business to produce market intelligence for the identification and development of proprietary products and ingredients.
ChromaDex has several compounds in its pipeline at various stages of development, the first of which is pterostilbene, currently marketed by the Company as an ingredient for inclusion in the products of other companies (pTeroPure) and as the basis for a retail line of dietary supplements (BluScience). Next-in-line compounds in the Company's pipeline, such as C3G, an anthocyanin, or nicotinamide riboside, also have commercial opportunity in multiple market channels.
